Janssen Pharmaceuticals is giving 340B entities refunds for overcharges on 14 NDCs during the third and fourth quarters of 2019, according to a public notice on the U.S. Health Resources and Services Administration (HRSA) website.
“The revisions were due to standard restatements of Medicaid pricing data,” the company’s notice said. Janssen is owned by pharmaceutical giant Johnson & Johnson.
Janssen’s refunds are on its antipsychotics Invega and Risperdal, blood thinner Xarelto, and Duragesic fentanyl patch. Kala’s is on its Inveltys eye drops for inflammation and pain after eye surgery.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
